MAPT and Alzheimer disease: We know mainly from AD research that CSF studies in patients with neurodegenerative disorders are feasible with a low rate of post LP headache or other complications (Andreasen et al., 2001) and CSF analysis for assessing tau protein and beta-amyloid belongs now to the standard of care in the management of dementias.